BrainsWay Secures First Insurance Coverage for Accelerated Deep TMS™ Protocol
BWAY has more than doubled off its 52-week low of $7.84.
Summary
BrainsWay announced that Premera Blue Cross Blue Shield will cover its accelerated SWIFT™ Deep TMS™ protocol for moderate to severe major depressive disorder, marking the first such policy from a payer.
Key Events · Product Development and Regulatory · BWAY
-
First Accelerated Deep TMS™ Coverage
Premera Blue Cross Blue Shield adopted a new medical policy covering BrainsWay's accelerated SWIFT™ Deep TMS™ protocol for moderate to severe major depressive disorder in patients aged 15 and older.
-
Expanded Market Access
This policy marks the first time a payer has covered the SWIFT™ protocol, which offers significantly fewer clinic days, potentially accelerating patient improvement and increasing adoption.
-
Significant Payer Reach
Premera Blue Cross Blue Shield covers over 2.8 million lives across Alaska and Washington state, representing a substantial market opportunity for BrainsWay.
Analysis · BWAY · Industrial Applications And Services
This is a highly significant development for BrainsWay, as securing the first insurance coverage policy for its accelerated SWIFT™ Deep TMS™ protocol from Premera Blue Cross Blue Shield opens a new pathway for market adoption and revenue growth. The policy, covering 2.8 million lives, validates the efficacy of the accelerated treatment and reduces barriers to access for patients aged 15 and older with major depressive disorder. This milestone could encourage other payers to follow suit, significantly expanding the addressable market for BrainsWay's innovative therapy.
At the time of this filing, BWAY was trading at $22.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $419.5M. The 52-week trading range was $7.84 to $21.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.